Validation of Classical Ayurvedic formulations in treatment of COVID-19

Phase 3

Not yet recruiting

• Conditions: Contact with and (suspected) exposure to other communicable diseases, (2) ICD-10 Condition: B972||Coronavirus as the cause of diseases classified elsewhere, (3) ICD-10 Condition: B972||Coronavirus as the cause of diseases classified elsewhere,

• Registration Number: CTRI/2020/06/026197
• Lead Sponsor: Ministry of AYUSH GoI

Brief Summary

The world is witnessing Global Pandemic COVID -19. The lack of approved effective drug therapeutic protocol for COVID-19 would be a challenge for the treatment of the newly merged COVID -19 infections world wide. Ayurveda medicine is already being used in many states to prevent and cure the disease. Aim of this proposal is to evaluate the efficacy of Sudarshan Ghan Vati and Vyaghradi Kwath in the management of mild to moderate symptoms of COVID-19 positive patients. The trial will be conducted at Government Ayurvedic Hospital, Department of ISM&H, Government of J&K, Indira Chowk, Jammu, Government Medical College, Bakshi Nagar, Jammu and 200 bedded (Maternity) designated COVID hospital, Gandhi Nagar, GMC, Jammu. This study will be collaborative with duration of three months. The subjects will be randomly divided in two groups: Conventional treatment group and Ayurvedic & Conventional group. Sample size would be 60 and intervention time will be one month. Ethical clearance and consent is already taken. Laboratory investigations , assessment and follow up will be done as per methodology. Financial burden can be reduced if the result is found positive.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-06-07
• Last Update Posted: 2022-04-27

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Patients of COVID-19 positive cases with mild to moderate symptoms 2.
• Patients who can take medicine orally 3.
• Patients willing to provide signed informed consent.

Exclusion Criteria

• Patients with severe symptom 2.
• Immuno compromised patients 3.
• Pregnant / Lactating females 4.
• COVID-19 negative patients.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Decrease in duration of conversion from COVID positive to negative	4 Weeks

Secondary Outcome Measures

Name	Time	Method
Improvement in Quality of Life	30 days

Trial Locations

Locations (1)

Goverment Medical College, Jammu; 🇮🇳 JAMMU, & KASHMIR, India

Goverment Medical College, Jammu

🇮🇳JAMMU, & KASHMIR, India

Dr Amanpreet Kaur

Principal investigator

9811933102

contactdramanpreet@gmail.com